Management of hypertension in chronic kidney disease

[1]  T. Hostetter,et al.  Single-Nephron Glomerular Filtration Rate in Healthy Adults. , 2017, The New England journal of medicine.

[2]  P. McFarlane,et al.  Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. , 2016, The Canadian journal of cardiology.

[3]  S. Textor,et al.  Uncontrolled hypertension by the 2014 evidence-based guideline: results from NHANES 2011–2012 , 2015, Journal of hypertension.

[4]  A. Go,et al.  Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  Kaleab Z. Abebe,et al.  Angiotensin blockade in late autosomal dominant polycystic kidney disease. , 2014, The New England journal of medicine.

[6]  Eric McArthur,et al.  Kidney function and population-based outcomes of initiating oral atenolol versus metoprolol tartrate in older adults. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  O. Carretero,et al.  Mechanism of impaired afferent arteriole myogenic response in Dahl salt-sensitive rats: role of 20-HETE. , 2014, American journal of physiology. Renal physiology.

[8]  K. Kalantar-Zadeh,et al.  Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. , 2014, JAMA internal medicine.

[9]  T. Kotchen,et al.  Role of sodium restriction and diuretic therapy for "resistant" hypertension in chronic kidney disease. , 2014, Seminars in nephrology.

[10]  M. Burnier,et al.  Ambulatory blood pressure and adherence monitoring: diagnosing pseudoresistant hypertension. , 2014, Seminars in nephrology.

[11]  S. Jacobson,et al.  Exercise training in adults with CKD: a systematic review and meta-analysis. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  S. Yusuf,et al.  Association of urinary sodium and potassium excretion with blood pressure. , 2014, The New England journal of medicine.

[13]  Mahboob Rahman,et al.  Assessment and management of hypertension in patients on dialysis. , 2014, Journal of the American Society of Nephrology : JASN.

[14]  D. Wonderling,et al.  Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance , 2014, BMJ : British Medical Journal.

[15]  M. Keane,et al.  Serum Aldosterone and Death, End-Stage Renal Disease, and Cardiovascular Events in Blacks and Whites: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study , 2014, Hypertension.

[16]  J. Sowers,et al.  The pathophysiology of hypertension in patients with obesity , 2014, Nature Reviews Endocrinology.

[17]  R. Townsend,et al.  Home blood pressure monitoring in CKD. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  W. Aronow.  Faculty Opinions recommendation of A controlled trial of renal denervation for resistant hypertension. , 2014 .

[19]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[20]  M. Cirillo,et al.  Parallel-Group 8-Week Study on Chlorthalidone Effects in Hypertensives With Low Kidney Function , 2014, Hypertension.

[21]  G. Jürgens,et al.  Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. , 2014, American journal of hypertension.

[22]  Graham A Colditz,et al.  The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. , 2014, JAMA surgery.

[23]  R. Agarwal,et al.  Chlorthalidone for Poorly Controlled Hypertension in Chronic Kidney Disease: An Interventional Pilot Study , 2014, American Journal of Nephrology.

[24]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[25]  J P Gassler,et al.  Baroreflex activation therapy in hypertension , 2014, Journal of Human Hypertension.

[26]  S. Crowley.  The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension. , 2014, Antioxidants & redox signaling.

[27]  K. Asayama,et al.  Night-time blood pressure is associated with the development of chronic kidney disease in a general population: the Ohasama Study , 2013, Journal of hypertension.

[28]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[29]  S. Pal,et al.  Potential benefits of exercise on blood pressure and vascular function. , 2013, Journal of the American Society of Hypertension : JASH.

[30]  B. Strom,et al.  Sodium Intake in Populations: Assessment of Evidence , 2013 .

[31]  R. Townsend,et al.  Arterial Stiffness, Kidney Function, and Chronic Kidney Disease Progression , 2013, Pulse.

[32]  W. Cushman,et al.  Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease , 2013, Annals of Internal Medicine.

[33]  Jeroen J. Bax,et al.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2013, European heart journal.

[34]  J. Coresh,et al.  Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States. , 2013, American heart journal.

[35]  M. Florescu,et al.  The impact of blood pressure variability on subclinical ventricular, renal and vascular dysfunction, in patients with hypertension and diabetes. , 2013, Maedica.

[36]  Simon L Bacon,et al.  The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2013, The Canadian journal of cardiology.

[37]  J. McMurray,et al.  Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study , 2013, Circulation. Heart failure.

[38]  Y. Toya,et al.  Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT) , 2013, Hypertension Research.

[39]  R. Loutzenhiser,et al.  Renal microvascular dysfunction, hypertension and CKD progression , 2013, Current opinion in nephrology and hypertension.

[40]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[41]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[42]  Y. Weijie,et al.  Relationship between Body Mass Index and Mortality in Hemodialysis Patients: A Meta-Analysis , 2012, Nephron Clinical Practice.

[43]  E. Schiffrin,et al.  Vascular Actions of Aldosterone , 2012, Journal of Vascular Research.

[44]  G. Schernthaner,et al.  Notice , 2012, Kidney International Supplements.

[45]  R. Agarwal.  Resistant hypertension and the neglected antihypertensive: sodium restriction. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  M. Weir,et al.  Thiazide and Thiazide-like Diuretics: An Opportunity to Reduce Blood Pressure in Patients with Advanced Kidney Disease , 2012, Current Hypertension Reports.

[47]  H. Krum,et al.  Renal denervation in moderate to severe CKD. , 2012, Journal of the American Society of Nephrology : JASN.

[48]  T. Holford,et al.  Chlorthalidone Compared With Hydrochlorothiazide in Reducing Cardiovascular Events: Systematic Review and Network Meta-Analyses , 2012, Hypertension.

[49]  P. Sanders,et al.  Effect of dietary salt on regulation of TGF-β in the kidney. , 2012, Seminars in nephrology.

[50]  Martin G Myers,et al.  Automated office blood pressure. , 2012, The Canadian journal of cardiology.

[51]  K. Dickstein,et al.  Aliskiren, ALTITUDE, and the implications for ATMOSPHERE , 2012, European journal of heart failure.

[52]  G. Bakris,et al.  Renal outcomes in hypertensive Black patients at high cardiovascular risk. , 2012, Kidney international.

[53]  G. Parati,et al.  Requirements for professional office blood pressure monitors , 2012, Journal of hypertension.

[54]  H. Kobori,et al.  The Link Between the Renin-Angiotensin-Aldosterone System and Renal Injury in Obesity and the Metabolic Syndrome , 2012, Current Hypertension Reports.

[55]  A. Garg,et al.  Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. , 2011, Journal of the American College of Cardiology.

[56]  G. Bakris,et al.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. , 2011, Journal of the American College of Cardiology.

[57]  R. Schrier,et al.  Blood pressure target in chronic kidney disease and proteinuria as an effect modifier. , 2011, Annals of internal medicine.

[58]  Merlin C. Thomas,et al.  An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. , 2011, Kidney international.

[59]  G. Navis,et al.  Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial , 2011, BMJ : British Medical Journal.

[60]  H. Black,et al.  Older blood pressure medications-do they still have a place? , 2011, The American journal of cardiology.

[61]  Giuseppe Conte,et al.  Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. , 2011, Archives of internal medicine.

[62]  J. Clarke,et al.  What is a systematic review? , 2011, Evidence Based Nursing.

[63]  J. Václavík,et al.  Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial , 2011, Hypertension.

[64]  Amy Earley,et al.  Systematic Review: Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect Modifier , 2011, Annals of Internal Medicine.

[65]  O. Carretero,et al.  The kallikrein-kinin system as a regulator of cardiovascular and renal function. , 2011, Comprehensive Physiology.

[66]  G. Dibona,et al.  Neural control of renal function. , 2011, Comprehensive Physiology.

[67]  J. Mariani,et al.  Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals , 2011, Journal of hypertension.

[68]  G. Mancia.  Prognostic value of long-term blood pressure variability: the evidence is growing. , 2011, Hypertension.

[69]  K. Reynolds,et al.  The Relationship Between Visit-to-Visit Variability in Systolic Blood Pressure and All-Cause Mortality in the General Population: Findings From NHANES III, 1988 to 1994 , 2011, Hypertension.

[70]  Keith C. Norris,et al.  Cardiovascular Disease in Chronic Kidney Disease: Data from the Kidney Early Evaluation Program (KEEP) , 2011, Current diabetes reports.

[71]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[72]  S. Nesbitt,et al.  Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. , 2010, Hypertension.

[73]  Jens Jordan,et al.  Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. , 2010, Journal of the American College of Cardiology.

[74]  J. Lewis.  Blood pressure control in chronic kidney disease: is less really more? , 2010, Journal of the American Society of Nephrology : JASN.

[75]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[76]  J. Cutler,et al.  Effects of intensive blood-pressure control in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[77]  G. Bakris,et al.  Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial , 2010, The Lancet.

[78]  Jens Jordan,et al.  Carotid Baroreceptor Stimulation, Sympathetic Activity, Baroreflex Function, and Blood Pressure in Hypertensive Patients , 2010, Hypertension.

[79]  J. Charleston,et al.  Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[80]  M. Esler.  The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. , 2010, Journal of applied physiology.

[81]  M. Godwin,et al.  Measurement of blood pressure in the office: recognizing the problem and proposing the solution. , 2010, Hypertension.

[82]  N. Poulter,et al.  Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents: A Meta-Analysis , 2010, Hypertension.

[83]  H. Abboud,et al.  Clinical practice. Stage IV chronic kidney disease. , 2010, The New England journal of medicine.

[84]  M. Moser,et al.  Use of diuretics in patients with hypertension. , 2009, The New England journal of medicine.

[85]  G. Navis,et al.  Benefits of dietary sodium restriction in the management of chronic kidney disease , 2009, Current opinion in nephrology and hypertension.

[86]  P. Schauer,et al.  Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[87]  A. Go,et al.  Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[88]  S. Oparil,et al.  Hypertension in the elderly. , 2009, Clinics in geriatric medicine.

[89]  R. Townsend.  F1000Prime recommendation of Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. , 2009 .

[90]  R. Whitbourn,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.

[91]  Yasmin,et al.  Aortic Calcification Is Associated With Aortic Stiffness and Isolated Systolic Hypertension in Healthy Individuals , 2009, Hypertension.

[92]  S. Navaneethan,et al.  Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[93]  S. Tobe,et al.  Comparison of two automated sphygmomanometers for use in the office setting , 2009, Blood pressure monitoring.

[94]  Mahboob Rahman,et al.  Disparate Estimates of Hypertension Control From Ambulatory and Clinic Blood Pressure Measurements in Hypertensive Kidney Disease , 2009, Hypertension.

[95]  B. Palmer.  Hypertension management in patients with chronic kidney disease , 2008, Current hypertension reports.

[96]  M. Joffe,et al.  Association between long-term blood pressure variability and mortality among incident hemodialysis patients. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[97]  D. Sica.  The Kidney and Hypertension: Causes and Treatment , 2008, Journal of clinical hypertension.

[98]  A. Mimran,et al.  Dietary sodium: the dark horse amongst cardiovascular and renal risk factors. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[99]  David Goff,et al.  Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. , 2008, Hypertension.

[100]  S. Oparil,et al.  Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. , 2008, Archives of internal medicine.

[101]  E. Lewis,et al.  Aliskiren combined with losartan in type 2 diabetes and nephropathy. , 2008, The New England journal of medicine.

[102]  Jongun Lee.  Nitric Oxide in the Kidney : Its Physiological Role and Pathophysiological Implications , 2008, Electrolyte & blood pressure : E & BP.

[103]  G. Navis,et al.  Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. , 2008, Journal of the American Society of Nephrology : JASN.

[104]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[105]  David Goff,et al.  Call to action on use and reimbursement for home blood pressure monitoring: executive summary a joint scientific statement from the american heart association, american society of hypertension, and preventive cardiovascular nurses association. , 2008, Journal of the American Society of Hypertension : JASH.

[106]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[107]  Yang Qiu,et al.  CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[108]  G. Kimura.  Kidney and circadian blood pressure rhythm. , 2008, Hypertension.

[109]  G. Bakris,et al.  Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[110]  A. Kshirsagar,et al.  Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[111]  R. Agarwal,et al.  Home blood pressures are of greater prognostic value than hemodialysis unit recordings. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[112]  H. Kobori,et al.  The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease , 2007, Pharmacological Reviews.

[113]  J. Filipovský,et al.  Diastolic Blood Pressure and Mortality in the Elderly With Cardiovascular Disease , 2007, Hypertension.

[114]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension , 2007, Blood pressure.

[115]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[116]  P. Verdecchia,et al.  Ambulatory Blood Pressure for Cardiovascular Risk Stratification , 2007, Circulation.

[117]  M. Glickman,et al.  Blood Pressure and Survival in the Oldest Old , 2007, Journal of the American Geriatrics Society.

[118]  R. Agarwal,et al.  Blood Pressure Recordings within and outside the Clinic and Cardiovascular Events in Chronic Kidney Disease , 2006, American Journal of Nephrology.

[119]  F. Elijovich.  20-HETE and salt-sensitivity of blood pressure a novel emerging concept. , 2006, American journal of hypertension.

[120]  F. Beyer,et al.  Potassium supplementation for the management of primary hypertension in adults. , 2006, The Cochrane database of systematic reviews.

[121]  R. Agarwal,et al.  Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. , 2006, Kidney international.

[122]  L. Ghiadoni,et al.  Thiazide diuretics in the treatment of hypertension: an update. , 2006, Journal of the American Society of Nephrology : JASN.

[123]  Gianfranco Parati,et al.  Prognostic relevance of blood pressure variability. , 2006, Hypertension.

[124]  Bryan Williams,et al.  Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials , 2006, Journal of hypertension.

[125]  Di Xie,et al.  Efficacy and safety of benazepril for advanced chronic renal insufficiency. , 2006, The New England journal of medicine.

[126]  G. Mensah,et al.  Sodium intake among people with normal and high blood pressure. , 2005, American journal of preventive medicine.

[127]  E. Lewis,et al.  Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. , 2005, Journal of the American Society of Nephrology : JASN.

[128]  Alice Stanton,et al.  Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality: The Dublin Outcome Study , 2005, Hypertension.

[129]  T. Ogihara,et al.  The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): Protocol, Patient Characteristics, and Blood Pressure during the First 12 Months , 2005, Hypertension Research.

[130]  G. Remuzzi,et al.  Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial , 2005, The Lancet.

[131]  G. Remuzzi,et al.  Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. , 2005, Journal of the American Society of Nephrology : JASN.

[132]  C. Delcroix,et al.  Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. , 2005, Journal of the American Society of Nephrology : JASN.

[133]  O. Mundler,et al.  A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[134]  I. Hajjar.  Postural Blood Pressure Changes and Orthostatic Hypotension in the Elderly Patient , 2005, Drugs & Aging.

[135]  S. Ishibashi,et al.  Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. , 2004, Kidney international.

[136]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[137]  R. Loutzenhiser,et al.  Systolic pressure and the myogenic response of the renal afferent arteriole. , 2004, Acta physiologica Scandinavica.

[138]  F. Cappuccio,et al.  Blood pressure control by home monitoring: meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.

[139]  G. Bakris,et al.  Differential effects of calcium antagonist subclasses on markers of nephropathy progression. , 2004, Kidney international.

[140]  Bruce Kupelnick,et al.  K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease , 2004 .

[141]  K. Kario,et al.  Sleep pulse pressure and awake mean pressure as independent predictors for stroke in older hypertensive patients. , 2004, American journal of hypertension.

[142]  C. Zoccali,et al.  Achievement of target blood pressure levels in chronic kidney disease: a salty question? , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[143]  T. Ohkubo,et al.  [The Ohasama study]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[144]  K. Bailey,et al.  Clinical decision-making in hypertension using an automated (BpTRU™) measurement device , 2003, Journal of Human Hypertension.

[145]  P. Blankestijn,et al.  Sympathetic nerve activity is inappropriately increased in chronic renal disease. , 2003, Journal of the American Society of Nephrology : JASN.

[146]  Robert Wolk,et al.  Obesity, Sleep Apnea, and Hypertension , 2003, Hypertension.

[147]  M. Pfeffer,et al.  Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) , 2003, European journal of heart failure.

[148]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[149]  T. Saruta,et al.  Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. , 2003, American journal of hypertension.

[150]  Christopher H Schmid,et al.  Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis , 2003, Annals of Internal Medicine.

[151]  T. Weinstein,et al.  The effects of weight loss on renal function in patients with severe obesity. , 2003, Journal of the American Society of Nephrology : JASN.

[152]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[153]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[154]  R. Hunt,et al.  Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. , 2002, The Canadian journal of cardiology.

[155]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[156]  J. Coresh,et al.  Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). , 2002, Journal of the American Society of Nephrology : JASN.

[157]  S. Textor,et al.  Resistant Hypertension: Comparing Hemodynamic Management to Specialist Care , 2002, Hypertension.

[158]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[159]  D. Sica.  Combination Calcium Channel Blocker Therapy in the Treatment of Hypertension , 2001, Journal of clinical hypertension.

[160]  W. White,et al.  Impact of smoking cessation on ambulatory blood pressure and heart rate in postmenopausal women. , 2001, American journal of hypertension.

[161]  Ann M. Johnson,et al.  Diuretics versus Angiotensin-Converting Enzyme Inhibitors in Autosomal Dominant Polycystic Kidney Disease , 2001, American Journal of Nephrology.

[162]  F. Berthoux,et al.  Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[163]  B. Prichard,et al.  Beta-Adrenergic Blocking Drugs in the Treatment of Hypertension , 2001, Blood pressure.

[164]  G. Bakris,et al.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[165]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[166]  A. Kshirsagar,et al.  Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[167]  W. Cushman,et al.  The role of diastolic blood pressure when treating isolated systolic hypertension. , 1999, Archives of internal medicine.

[168]  T. Heise,et al.  Value of blood pressure self-monitoring as a predictor of progression of diabetic nephropathy. , 1999, Journal of hypertension.

[169]  G. Remuzzi,et al.  Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). , 1998, Journal of the American Society of Nephrology : JASN.

[170]  T A Kotchen,et al.  Dietary electrolytes and blood pressure: a statement for healthcare professionals from the American Heart Association Nutrition Committee. , 1998, Circulation.

[171]  T. Uzu,et al.  Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. , 1997, Circulation.

[172]  T. Hostetter,et al.  Role of aldosterone in the remnant kidney model in the rat. , 1996, The Journal of clinical investigation.

[173]  E. Mutschler,et al.  Diuretic Effectiveness of Hydrochlorothiazide and Furosemide Alone and in Combination in Chronic Renal Failure , 1995, Journal of cardiovascular pharmacology.

[174]  A. Goldberg,et al.  Salt-Induced Increases in Systolic Blood Pressure Affect Renal Hemodynamics and Proteinuria , 1995 .

[175]  G. Reboldi,et al.  Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. , 1994, Hypertension.

[176]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[177]  R. Converse,et al.  Sympathetic overactivity in patients with chronic renal failure. , 1992, The New England journal of medicine.

[178]  K. Shimada,et al.  Silent Cerebrovascular Disease in the Elderly Correlation With Ambulatory Pressure , 1990, Hypertension.

[179]  M. Blaufox,et al.  Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. , 1989, Hypertension.

[180]  B. Brenner,et al.  Progressive renal disease: a disorder of adaptation. , 1989, The Quarterly journal of medicine.

[181]  B. Brenner,et al.  Therapeutic benefit of converting-enzyme inhibition in progressive renal disease. , 1988, American journal of hypertension.

[182]  G. Scally.  Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. , 1988, BMJ.

[183]  Jeremiah Stamler,et al.  Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. , 1988 .

[184]  N. Madias,et al.  Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. , 1983, The New England journal of medicine.

[185]  D. Blackwood,et al.  Valproate levels in children with epilepsy. , 1982, Lancet.

[186]  J. Roos,et al.  Salt Sensitivity of Blood Pressure in Chronic Renal Failure: Evidence for Renal Control of Body Fluid Distribution in Man , 1982, Hypertension.

[187]  R. Kane,et al.  Long‐Term Diuretic Therapy with Metolazone of Renal Failure and the Nephrotic Syndrome , 1977, Journal of clinical pharmacology.

[188]  J. Borst,et al.  Hypertension explained by Starling's theory of circulatory homoeostasis. , 1963, Lancet.

[189]  Bertrand K. Hassani.  The Consensus Approach , 2016 .

[190]  C. Wilcox,et al.  Oxidative stress in hypertension: role of the kidney. , 2014, Antioxidants & redox signaling.

[191]  J. N. Sharma,et al.  The kallikrein-kinin pathways in hypertension and diabetes. , 2014, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[192]  A. Schutte,et al.  Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. , 2014, Journal of hypertension.

[193]  K. Amann,et al.  Structural renal changes in obesity and diabetes. , 2013, Seminars in nephrology.

[194]  W. Cullen,et al.  What is a randomised controlled trial? , 2013, Irish medical journal.

[195]  G. Keating,et al.  Moxonidine , 2012, Drugs.

[196]  A. Whaley-connell,et al.  The importance of early identification of chronic kidney disease. , 2011, Missouri medicine.

[197]  W. Elliott.  Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement , 2011 .

[198]  M. Godwin,et al.  Recognizing the Problem and Proposing the Solution , 2010 .

[199]  W. J. Elliott,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2010 .

[200]  R. Kunz,et al.  Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal Disease , 2008, Annals of Internal Medicine.

[201]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[202]  K. Griendling,et al.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. , 2007, American journal of physiology. Cell physiology.

[203]  C. DeWitt,et al.  Pharmacology, Pathophysiology and Management of Calcium Channel Blocker and β-Blocker Toxicity , 2004, Toxicological reviews.

[204]  W. Frishman,et al.  β-Adrenergic Blockers in Systemic Hypertension , 2002 .

[205]  S. Textor,et al.  Comparing Hemodynamic Management to Specialist Care , 2002 .

[206]  T. Ishimitsu,et al.  Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. , 1999, Hypertension.

[207]  G. Beck,et al.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. , 1994, The New England journal of medicine.

[208]  K. Ando,et al.  Norepinephrine responsiveness in patients with borderline hypertension under three different sodium balances. , 1989, Clinical and experimental hypertension. Part A, Theory and practice.

[209]  R. Heel,et al.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. , 1986, Drugs.

[210]  J. O. Davis,et al.  Mechanisms regulating renin release. , 1976, Physiological reviews.

[211]  J. Laragh,et al.  The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. , 1975, The American journal of medicine.

[212]  J. Conn.  Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. , 1955, The Journal of laboratory and clinical medicine.

[213]  C. Richter.  Rheumatology 2006;45:iii36–iii38 Role , 2022 .

[214]  Annals of Internal Medicine Original Research Chlorthalidone Versus Hydrochlorothiazide for the Treatment of Hypertension in Older Adults A Population-Based Cohort Study , 2022 .

[215]  Yoshihiko Saito,et al.  Vascular Health and Risk Management Dovepress Effects of Smoking Cessation on Central Blood Pressure and Arterial Stiffness , 2022 .

[216]  R. Wachter,et al.  Original Report: Patient-oriented, Translational Research Impact of Baroreflex Activation Therapy on Renal Function – a Pilot Study , 2022 .